{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:39:27Z","timestamp":1790854767295,"version":"4.1.0"},"reference-count":64,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Forschung, Technologie und Raumfahrt","doi-asserted-by":"crossref","award":["01KG2415"],"award-info":[{"award-number":["01KG2415"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns3:p>\n                    Background There are currently no sex-specific recommendations for antipsychotic prescribing in schizophrenia, although women may be more susceptible to certain side-effects and may require lower doses to achieve comparable efficacy to men. However, sex differences remain insufficiently studied to inform treatment decisions. Methods We plan a systematic review and individual-participant-data meta-analysis of randomized trials comparing different antipsychotic drugs, doses, formulations with each other or with placebo in adults with acute schizophrenia. Eligible studies will be identified through the Vivli platform, and their individual-participant-data will be harmonized into a common dataset. Two independent reviewers will screen search results and assess risk of bias using the Risk of Bias 2 tool. The primary outcome will be overall symptoms of schizophrenia, and secondary outcomes will include a broad range of efficacy, tolerability, acceptability, and dosing measures. A stepwise approach to data synthesis will be adopted, depending on individual-participant-data availability, aiming to examine sex differences in the effects of antipsychotic drugs compared to placebo. If sufficient data are available, we will conduct random-effects meta-analyses using regression models to evaluate biological sex, typically categorised as male or female, as both a prognostic factor and an effect modifier, network meta-analyses to synthesize direct and indirect evidence, and dose-response meta-analyses using restricted cubic splines to explore dose-effect relationships. The robustness of the findings will be assessed through sensitivity analyses adjusting for additional covariates. The certainty of evidence on sex differences will be evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach for subgroup analysis. If the certainty is judged to be moderate or high, sex-specific treatment effects will be further assessed using the Confidence in Network Meta-Analysis (CINeMA) framework. Discussion This study will examine sex differences in the efficacy, tolerability, and dosing of antipsychotics in acute schizophrenia, potentially contributing to evidence-based, sex-specific treatment recommendations for antipsychotic prescribing.\n                    <ns3:bold>Protocol registration<\/ns3:bold>\n                    PROSPERO-ID: CRD420251022957\n                  <\/ns3:p>","DOI":"10.12688\/f1000research.169873.1","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T09:25:06Z","timestamp":1758619506000},"page":"967","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Sex differences in the efficacy and tolerability of antipsychotic drugs in people with an acute exacerbation of schizophrenia: protocol for an individual-participant-data, dose-response, network meta-analysis"],"prefix":"10.12688","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8264-2039","authenticated-orcid":false,"given":"Spyridon","family":"Siafis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3448-9532","authenticated-orcid":false,"given":"Johannes","family":"Schneider-Thoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia E.","family":"Fares-Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bram W. C.","family":"Storosum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper B.","family":"Zantvoord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horst","family":"Naiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl Heinz","family":"M\u00f6hrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Priller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3963-1654","authenticated-orcid":false,"given":"John M.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orestis","family":"Efthimiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Salanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4934-4352","authenticated-orcid":false,"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"ref1","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.","author":"M Huhn","year":"2019 Jul 11","journal-title":"Lancet."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"649-663","DOI":"10.1017\/S0033291721004591","article-title":"Antipsychotic medication for women with schizophrenia spectrum disorders.","volume":"52","author":"B Brand","year":"2022 Mar","journal-title":"Psychol. Med."},{"key":"ref3","doi-asserted-by":"crossref","first-page":"723-733","DOI":"10.1007\/s11920-023-01460-6","article-title":"Evidence-Based Recommendations for the Pharmacological Treatment of Women with Schizophrenia Spectrum Disorders.","volume":"25","author":"B Brand","year":"2023 Nov","journal-title":"Curr. Psychiatry Rep."},{"key":"ref4","doi-asserted-by":"crossref","first-page":"937-948","DOI":"10.1093\/schbul\/sbn023","article-title":"Secondary effects of antipsychotics: women at greater risk than men.","volume":"35","author":"M Seeman","year":"2009 Sep","journal-title":"Schizophr. Bull."},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1324-1333","DOI":"10.1176\/appi.ajp.161.8.1324","article-title":"Gender differences in the prescribing of antipsychotic drugs.","volume":"161","author":"M Seeman","year":"2004 Aug","journal-title":"Am. J. Psychiatry."},{"key":"ref6","doi-asserted-by":"crossref","first-page":"330-336","DOI":"10.1016\/S2215-0366(21)00383-7","article-title":"Towards better care for women with schizophrenia-spectrum disorders.","volume":"9","author":"B Brand","year":"2022 Apr","journal-title":"Lancet Psychiatry."},{"key":"ref7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41537-020-0102-z","article-title":"The clinical course of schizophrenia in women and men-a nation-wide cohort study.","volume":"6","author":"I Sommer","year":"2020 May 1","journal-title":"NPJ Schizophr."},{"key":"ref8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41537-021-00170-3","article-title":"Sex differences in antipsychotic efficacy and side effects in schizophrenia spectrum disorder: results from the BeSt InTro study.","volume":"7","author":"S Hoekstra","year":"2021 2021\/08\/18","journal-title":"NPJ Schizophr."},{"key":"ref9","doi-asserted-by":"crossref","first-page":"559-570","DOI":"10.1007\/s40263-024-01089-w","article-title":"Sex Differences Between Female and Male Individuals in Antipsychotic Efficacy and Adverse Effects in the Treatment of Schizophrenia.","volume":"38","author":"M Galbally","year":"2024 Jul","journal-title":"CNS Drugs."},{"key":"ref10","doi-asserted-by":"crossref","first-page":"225-231","DOI":"10.1016\/j.psychres.2006.09.016","article-title":"Gender differences in response to antipsychotic treatment in outpatients with schizophrenia.","volume":"153","author":"J Usall","year":"2007 Dec 3","journal-title":"Psychiatry Res."},{"key":"ref11","doi-asserted-by":"crossref","first-page":"136-143","DOI":"10.1093\/schbul\/sbac139","article-title":"Women with Schizophrenia-Spectrum Disorders After Menopause: A Vulnerable Group for Relapse.","volume":"49","author":"I Sommer","year":"2023 Jan 3","journal-title":"Schizophr. Bull."},{"key":"ref12","first-page":"884-893","article-title":"The response of subgroups of patients with schizophrenia to different antipsychotic drugs: a systematic review and meta-analysis. Lancet.","volume":"9","author":"S Leucht","year":"2022 Nov","journal-title":"Psychiatry."},{"key":"ref13","doi-asserted-by":"crossref","first-page":"171-192","DOI":"10.1016\/j.jad.2024.02.038","article-title":"Sex differences in effectiveness and adverse effects of mood stabilizers and antipsychotics: A systematic review.","volume":"352","author":"M Ercis","year":"2024 May 1","journal-title":"J. Affect. Disord."},{"key":"ref14","doi-asserted-by":"crossref","first-page":"114997","DOI":"10.1016\/j.psychres.2022.114997","article-title":"Gender differences in the response to antipsychotic medication in patients with schizophrenia: An individual patient data meta-analysis of placebo-controlled studies.","volume":"320","author":"B Storosum","year":"2023 Feb","journal-title":"Psychiatry Res."},{"key":"ref15","doi-asserted-by":"crossref","first-page":"e308-e316","DOI":"10.4088\/JCP.13m08853","article-title":"Determinants of antipsychotic response in schizophrenia: implications for practice and future clinical trials.","volume":"75","author":"J Rabinowitz","year":"2014 Apr","journal-title":"J. Clin. Psychiatry."},{"key":"ref16","first-page":"40-49","article-title":"Antipsychotic-induced akathisia in adults with acute schizophrenia: A systematic review and dose-response meta-analysis.","volume":"72","author":"H Wu","year":"2023 Jul","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref17","first-page":"643-654","article-title":"Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials.","volume":"48","author":"H Wu","year":"2022 May 7","journal-title":"Schizophr. Bull."},{"key":"ref18","doi-asserted-by":"crossref","first-page":"3267-3277","DOI":"10.1038\/s41380-023-02203-y","article-title":"Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis.","volume":"28","author":"S Siafis","year":"2023 Aug","journal-title":"Mol. Psychiatry."},{"key":"ref19","doi-asserted-by":"crossref","first-page":"342-353","DOI":"10.1176\/appi.ajp.2019.19010034","article-title":"Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.","volume":"177","author":"S Leucht","year":"2020 Apr 1","journal-title":"Am. J. Psychiatry."},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1238-1248","DOI":"10.1001\/jamapsychiatry.2021.2130","article-title":"Examination of Dosing of Antipsychotic Drugs for Relapse Prevention in Patients With Stable Schizophrenia: A Meta-analysis.","volume":"78","author":"S Leucht","year":"2021 Nov 1","journal-title":"JAMA Psychiatry."},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2411-2413","DOI":"10.1056\/NEJMp1605348","article-title":"A global, neutral platform for sharing trial data.","volume":"374","author":"B Bierer","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s41073-016-0007-6","article-title":"Sex and Gender Equity in Research: rationale for the SAGER guidelines and recommended use.","volume":"1","author":"S Heidari","year":"2016 2016\/05\/03","journal-title":"Research Integrity and Peer Review."},{"key":"ref23","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation.","volume":"349","author":"L Shamseer","year":"2015","journal-title":"BMJ: British Medical Journal."},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1064-1071","DOI":"10.1001\/jamapsychiatry.2020.1596","article-title":"Association of End Point Definition and Randomized Clinical Trial Duration in Clinical Trials of Schizophrenia Medications.","volume":"77","author":"I Younis","year":"2020 Oct 1","journal-title":"JAMA Psychiatry."},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1411-1413","DOI":"10.1007\/s00406-021-01335-y","article-title":"Should \u2018typical\u2019, first-generation antipsychotics no longer be generally used in the treatment of schizophrenia?","volume":"271","author":"S Leucht","year":"2021 Dec","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"ref28","doi-asserted-by":"crossref","first-page":"982-991","DOI":"10.1177\/02698811231205688","article-title":"Second International Consensus Study of Antipsychotic Dosing (ICSAD-2).","volume":"37","author":"M McAdam","year":"2023 Oct","journal-title":"J. Psychopharmacol."},{"key":"ref29","doi-asserted-by":"crossref","first-page":"403-405","DOI":"10.1056\/NEJMp1607342","article-title":"The Yale Open Data Access (YODA) project--a mechanism for data sharing.","volume":"375","author":"H Krumholz","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref30","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"M Page","year":"2021 Mar 29","journal-title":"BMJ."},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1657-1665","DOI":"10.1001\/jama.2015.3656","article-title":"Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement.","volume":"313","author":"L Stewart","year":"2015 Apr 28","journal-title":"JAMA."},{"key":"ref32","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"J Sterne","year":"2019 Aug 28","journal-title":"BMJ."},{"key":"ref33","doi-asserted-by":"crossref","first-page":"561-568","DOI":"10.1016\/j.biopsych.2023.04.004","article-title":"Data-Driven Taxonomy for Antipsychotic Medication: A New Classification System.","volume":"94","author":"R McCutcheon","year":"2023 Oct 1","journal-title":"Biol. Psychiatry."},{"key":"ref34","doi-asserted-by":"crossref","first-page":"824-836","DOI":"10.1016\/S0140-6736(21)01997-8","article-title":"Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis.","volume":"399","author":"J Schneider-Thoma","year":"2022 Feb 26","journal-title":"Lancet."},{"key":"ref35","first-page":"261-276","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia.","volume":"13","author":"S Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"ref36","doi-asserted-by":"crossref","first-page":"799-812","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale.","volume":"10","author":"J Overall","year":"1962","journal-title":"Psychol. Rep."},{"key":"ref37","doi-asserted-by":"crossref","first-page":"249-252","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia.","volume":"176","author":"M Marshall","year":"2000 Mar","journal-title":"Br. J. Psychiatry."},{"key":"ref38","doi-asserted-by":"crossref","first-page":"956-959","DOI":"10.1016\/j.euroneuro.2012.11.004","article-title":"Equipercentile linking of the BPRS and the PANSS.","volume":"23","author":"S Leucht","year":"2013 Aug","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref39","doi-asserted-by":"crossref","first-page":"231-238","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"S Leucht","year":"2005 Nov 15","journal-title":"Schizophr. Res."},{"key":"ref41","doi-asserted-by":"crossref","first-page":"109-117","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA).","volume":"20","author":"E Brown","year":"1999 Feb","journal-title":"Drug Saf."},{"key":"ref42","first-page":"9-62","article-title":"Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.","volume":"51","author":"C Hiemke","year":"2018 Jan","journal-title":"Pharmacopsychiatry."},{"key":"ref43","doi-asserted-by":"crossref","first-page":"398-419","DOI":"10.1002\/jrsm.1347","article-title":"Pitfalls of using the risk ratio in meta-analysis.","volume":"10","author":"I Bakbergenuly","year":"2019 Sep","journal-title":"Res. Synth. Methods."},{"key":"ref44","doi-asserted-by":"crossref","first-page":"27-36","DOI":"10.1093\/schbul\/sbab094","article-title":"How Efficacious Are Antipsychotic Drugs for Schizophrenia? An Interpretation Based on 13 Effect Size Indices.","volume":"48","author":"S Leucht","year":"2022","journal-title":"Schizophr. Bull."},{"key":"ref45","first-page":"9622802211070256","article-title":"A dose-effect network meta-analysis model with application in antidepressants using restricted cubic splines.","author":"T Hamza","year":"2022 Feb 24","journal-title":"Stat. Methods Med. Res."},{"key":"ref47","doi-asserted-by":"crossref","first-page":"5203-5219","DOI":"10.1002\/sim.9562","article-title":"Network meta-analysis of rare events using penalized likelihood regression.","volume":"41","author":"T Evrenoglou","year":"2022 Nov 20","journal-title":"Stat. Med."},{"key":"ref48","first-page":"236-263","article-title":"GetReal in network meta-analysis: a review of the methodology. Res Synth.","volume":"7","author":"O Efthimiou","year":"2016 Sep","journal-title":"Methods."},{"key":"ref49","first-page":"1-67","article-title":"mice: Multivariate imputation by chained equations in R.","volume":"45","author":"S Van Buuren","year":"2011","journal-title":"J. Stat. Softw."},{"key":"ref51","doi-asserted-by":"crossref","first-page":"991-996","DOI":"10.1016\/j.jclinepi.2007.11.010","article-title":"Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry.","volume":"61","author":"J Peters","year":"2008 Oct","journal-title":"J. Clin. Epidemiol."},{"key":"ref52","doi-asserted-by":"crossref","first-page":"70-83","DOI":"10.1016\/j.jclinepi.2023.03.003","article-title":"GRADE guidance 36: updates to GRADE\u2019s approach to addressing inconsistency.","volume":"158","author":"G Guyatt","year":"2023 Jun","journal-title":"J. Clin. Epidemiol."},{"key":"ref53","doi-asserted-by":"crossref","first-page":"E901-e6","DOI":"10.1503\/cmaj.200077","article-title":"Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses.","volume":"192","author":"S Schandelmaier","year":"2020 Aug 10","journal-title":"CMAJ."},{"key":"ref54","doi-asserted-by":"crossref","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: An approach for assessing confidence in the results of a network meta-analysis.","volume":"17","author":"A Nikolakopoulou","year":"2020 Apr","journal-title":"PLoS Med."},{"key":"ref55","article-title":"R: A language and environment for statistical computing.","year":"2013"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"153-160","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial.","volume":"22","author":"S Balduzzi","year":"2019 Nov","journal-title":"Evid. Based Ment. Health."},{"key":"ref57","doi-asserted-by":"crossref","first-page":"1-40","DOI":"10.18637\/jss.v106.i02","article-title":"netmeta: An R Package for Network Meta-Analysis Using Frequentist Methods.","volume":"106","author":"S Balduzzi","year":"2023 03\/23","journal-title":"J. Stat. Softw."},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1-15","DOI":"10.18637\/jss.v072.c01","article-title":"Multivariate dose-response meta-analysis: the dosresmeta R package.","volume":"72","author":"A Crippa","year":"2016","journal-title":"J. Stat. Softw."},{"key":"ref59","article-title":"crossnma: Cross-Design and Cross-Format Synthesis using Network Meta-Analysis and Network Meta-Regression.","author":"T Hamza","year":"2022"},{"key":"ref60","article-title":"JAGS: A program for analysis of Bayesian graphical models using Gibbs sampling.","volume":"2003","year":"2003"},{"key":"ref61","article-title":"rjags: Bayesian graphical models using MCMC. R package version.","volume":"4","author":"M Plummer","year":"2016"},{"key":"ref62","first-page":"358","article-title":"GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research.","author":"S Staniszewska","year":"2017","journal-title":"BMJ."},{"key":"ref63","doi-asserted-by":"crossref","first-page":"777-784","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.","volume":"162","author":"B Hutton","year":"2015 Jun 2","journal-title":"Ann. Intern. Med."},{"key":"ref64","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1186\/s12888-022-04036-5","article-title":"Evidence-based Shared-Decision-Making Assistant (SDM-assistant) for choosing antipsychotics: protocol of a cluster-randomized trial in hospitalized patients with schizophrenia.","volume":"22","author":"S Siafis","year":"2022 Jun 17","journal-title":"BMC Psychiatry."},{"key":"ref65","doi-asserted-by":"crossref","first-page":"1629-1631","DOI":"10.1007\/s00406-023-01712-9","article-title":"Shared Decision Making Assistant (SDMA) and other digital tools for choosing antipsychotics in schizophrenia treatment.","volume":"273","author":"S Leucht","year":"2023 Dec","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"ref66","doi-asserted-by":"crossref","first-page":"1-9","DOI":"10.1038\/sdata.2016.18","article-title":"The FAIR Guiding Principles for scientific data management and stewardship.","volume":"3","author":"M Wilkinson","year":"2016","journal-title":"Sci. Data."},{"key":"ref67","doi-asserted-by":"crossref","first-page":"97-108","DOI":"10.3390\/women1020009","article-title":"Sex Selection Bias in Schizophrenia Antipsychotic Trials\u2014An Update Systematic Review.","volume":"1","author":"L Fonseca","year":"2021","journal-title":"Women."},{"key":"ref68","doi-asserted-by":"crossref","first-page":"650904","DOI":"10.3389\/fpsyt.2021.650904","article-title":"The Pharmacodynamics of Antipsychotic Drugs in Women and Men.","volume":"12","author":"M Seeman","year":"2021","journal-title":"Front. Psych."},{"key":"ref69","article-title":"Protocol for meta-analysis on sex differences in antipsychotic effects (APSEDI).","author":"S Siafis","year":"2025","journal-title":"Zenodo."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/14-967\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/14-967\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/14-967\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T10:34:20Z","timestamp":1768991660000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/14-967\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":64,"URL":"https:\/\/doi.org\/10.12688\/f1000research.169873.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.187258.r436552","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.187258.r443741","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.187258.r436552","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.187258.r443741","asserted-by":"object"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/14-967\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.187258.r443741, Mete Ercis, Mayo Clinic, Rochester, MN, 27 Dec 2025, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/14-967\/v1#referee-response-443741","order":0,"name":"referee-response-443741","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.187258.r436552, Rosa Catal\u00e1n, Barcelona Clinic Schizophrenia Unit (BCSU), Neurosciences Institute, Hospital Cl\u00ednic of Barcelona, University of Barcelona, IDIBAPS, Barcelona, 21 Jan 2026, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/14-967\/v1#referee-response-436552","order":1,"name":"referee-response-436552","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"This project was funded by the German Federal Ministry of Research, Technology and Space (Bundesministerium f\u00fcr Forschung, Technologie und Raumfahrt, BMFTR; grant number 01KG2415). The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}